

A Review of Literature on the Adverse Effects of Hyperthyroidism on the Heart Functional Behavior

Azad Reza Mansourian

Biochemistry and Metabolic Disorder Research Center,
Gorgan Medical School, Golestan University of Medical Sciences, Gorgan, Iran

Abstract: Thyroid hormones play an important role on the physiological chemistry of heart and vascular systems in healthy subjects. Any thyroid disorders accompanied with alteration with effective concentration of thyroid hormones cause heart dysfunctions. Thyrotoxicosis is a term given for the clinical manifestation of hyperthyroidism which can invoke heart and vascular abnormalities through the mechanism at heart muscle cells nuclear level. Thyrotoxicosis can play positive roles for heart disorders including atrial fibrillation, left ventricular hypertrophy and right ventricular systolic dysfunction, which are considered as major risk factors for heart abnormalities. Miscalculation of heart dysfunctions related thyrotoxicosis in cardiovascular patients might be avoided through careful laboratory measurements of T4 and T3 to exclude any possible thyroid hormone-related heart diseases.

Key words: Thyroid hormones, thyrotoxicosis, heart dysfunction

INTRODUCTION

Thyroid produce two important hormones of tetraiodothyronine or thyroxine (T4) and triiodo-thyroxine or (T3) but it is the T3 which can be considered as the potent hormone direct the normal physiology of the heart system. The T4 and T3 both are synthesized within the thyroid gland but T3 itself can be produced from deiodination of T4 in peripheral tissue whether T3 which in stimulating heart is originating from thyroid or it is synthesized from T4 within the heart muscle is not a matter for any critical argument but how thyroid hormones can direct the patho-physiology of heart function which is the prime concern and will be elaborated.

Thyrotoxicosis which is definition for collective clinical manifestation of hyperthyroidism, are among cause of heart morbidity and mortality and thyroid hormones excess are responsible for many cardiovascular diseases (Kaminski *et al.*, 2012; Kim *et al.*, 2011; Brandt *et al.*, 2011; Mansourian 2010a, b; Everts *et al.*, 1996; Brent, 1994; Makino *et al.*, 2012; Parma *et al.*, 1995; Emrich *et al.*, 1993). The eventual outcome of thyroid hormone on heart muscles is through the hormonal action on myocyte predispose mainly to the T3, which is universally is accepted pathway, happen through penetration of T3 through cell membrane and binding to the specific receptors partly believed located within the nucleus of target cells. The combined T3-Receptor is behaving similar, to steroid hormones, bind to the specific site on the DNA of heart muscle cells.

(Mansourian, 2010a, b, 2012; Kim *et al.*, 2011; Mansourian, 2010a, b; Studer and Ramelli, 1982; Studer *et al.*, 1989; Bogazzi *et al.*, 1999; Klein and Hong, 1986; Klein, 1990; Park *et al.*, 1997; Polikaretal., 1993).

Therefore, it can be confidently mentioned that T3 stimulate its mechanism at cellular level, with subsequent gene expression of particular proteins within the cardiovascular cells and there are various reports in this area of heart physiology (Mariottr Ladensen *et al.*, Klein and Ojamaa, 2000; Markin, 1993; Dratman and Grodon, 1996; Nayak and Burman, 2006; Maji, 2006; Shimatsu *et al.*, 1999).

Following T3 physiological action at myocytes of heart muscle, proteins are translated from transcribed messenger ribonucleic acid (mRNA) and those protein play the vital role in heart functions and various physiological process within cardiovascular systems. In a postulated scenario, when the respected gene within the myocytes is not activated due to the either of T3 under production or even diminished T3 receptor within the myocytes, the adverse effects include many disorders ranging from abnormality in contraction and calcium regulation in cardiac muscle occur due to the alteration of myosin synthesis and enzyme level responsible for calcium (Mansourian, 2012; Mansourian, 2010a, b; Fadel *et al.*, 2000; Brent, 1994; Ojamaa *et al.*, 1996; Markin, 1993; Magner *et al.*, 1988; Dillmann, 1990; Mintz *et al.*, 1991; Kiss *et al.*, 1994; Ojamaa *et al.*, 2000; Kiss *et al.*, 1998; Ladenson *et al.*, 1992; Klein and Ojamaa, 2000).

Calcium-ATPase, is an enzyme responsible for active relocation of ionized calcium (Ca^{2+}) into sarcoplasmic reticulum and it is the vital factor for the critical physiological pathways of myocytes, namely known as systolic diastolic function of the heart (Mansourian, 2012; Taillard *et al.*, 2011; Little *et al.*, 1990; Gillebert *et al.*, 2000; Wong *et al.*, 2011; Dillmann, 1990; Mintz *et al.*, 1991; Kiss *et al.*, 1994). The relocation of Ca^{2+} into the sarcoplasmic reticulum of myocytes is occurred through some transport protein which is produced by the metabolic action of T3 on the myocytes. In thyroid related diseases, which can be varied and can be due to many disorders within thyroid gland itself if it is primary thyroid dysfunction and secondary on cases the other factors causing the alteration of thyroid hormones cardiac diastolic procedures maybe modified with eventual disruption of heart function (Mansourian, 2012; Dillmann, 1990; Mintz *et al.*, 1991; Kiss *et al.*, 1994; Ojamaa *et al.*, 2000; Bogazzi *et al.*, 1999; Kinney *et al.*, 1988; Karger and Fuherer, 2008; Cooper, 2003; Persani *et al.*, 2000).

Phospholamban is the protein responsible for the Ca^{2+} relocation, within cardiac myocytes into sarcoplasmic reticulum which is mediated by calcium-activated ATPase. It seems any function to modify the level of phospholamban eventually lead to the disruption of relaxation which is the proposed physiological role, for diastolic function (Kim *et al.*, 2011; Kaminski *et al.*, 2012; Kiss *et al.*, 1994; Ojamaa *et al.*, 2000; Kiss *et al.*, 1998; Mintz *et al.*, 1991).

Also thyroid hormone play key role in systolic diastolic function through ionized calcium Ca^{2+} release and the subsequent re-uptake by the sarcoplasmic reticulum but other proteins are produced by the action of thyroid hormone at cardiac myocyte within the heart which ultimately are playing key roles in the regulation of the either of electrochemical and mechanical function of heart muscles (Mansourian, 2010c, 2012; Gick *et al.*, 1990; Ojamaa *et al.*, 1999).

In addition to what was mentioned about the key role of T3 on cardiac myocytes and producing proteins such as myosin to have structural responsibilities and calcium-activated ATPase and related protein for release and re-uptake of ionized calcium into the sarcoplasmic reticulum. T3 also have other function on the heart muscle, independent of gene and nuclear level; including modification of ionized sodium, potassium and calcium channels in the heart muscle to the extend, which, can eventually regulate the well being of heart myocytes in normal physiological conditions. The elevation and suppression in the amount of thyroid hormone and the alteration of above parameters directly will relate to the

heart biochemical and physiological pathway changes which eventually lead to cardiac disorders (Mansourian, 2010a, b; Hendriksen and Petersen, 1995; Petretta *et al.*, 2001; Diao *et al.*, 1998; Roffi *et al.*, 2005; Aksnes, 1994; Kaminski *et al.*, 2012; Chen *et al.*, 2006; Hurley *et al.*, 1981; Schmidt-Ott and Ascheim, 2006; Yue *et al.*, 2011).

Accordingly, it seems, any alteration in the amount of T3 which can be due to many thyroid dysfunction and even therapeutic regimen leading to thyrotoxicosis can subsequently alter the normal physiological mechanism of heart function. In case of hyperthyroidism, which is the purpose of this review, the structural and regulation of cardiac function modified, to the extend that increased cardiac rate and increased in blood volume, pulse pressure, increased heart output volume. are among some irregularities of elevated T3 with its subsequent function on the heart muscles (Mansourian, 2010a, b; Rizzo and Bruno, 2012; Waring *et al.*, 2012; Kaminski *et al.*, 2012; Kim *et al.*, 2011; Brandt *et al.*, 2011; Davis and Davis, 1993; Walker *et al.*, 1994; Klemperer *et al.*, 1996; Graettinger *et al.*, 1959; Biondi *et al.*, 1994; Mintz *et al.*, 1991; Klein and Ojamaa, 1998; Cacciatori *et al.*, 1996; Nordyke *et al.*, 1988; Polikar *et al.*, 1993, 1934; Graettinger *et al.*, 1959; Feldman *et al.*, 1986; Klein and Ojamaa, 2000).

The eventual consequence of thyroid hormone on the heart function can be based on the physiological elevation rate of left ventricular of systolic-diastolic contraction. As it was mentioned earlier later pathway occurred through the straight metabolic effect of T4 and T3 on heart myocytes cell, with the production of protein responsible for the contraction and other physiological function which is mediated through ionized Calcium regulatory mechanism (Bird-Lake 2011; Yue *et al.*, 2011; Schmidt-Ott and Ascheim, 2006; Wong *et al.*, 2011; Diao *et al.*, 1998; Little *et al.*, 1990; Taillard *et al.* 2011; Aksnes, 1994; Franklyn and Gammage, 2007; Gillebert *et al.*, 2000; Morkin, 1993; Ojamaa *et al.*, 2000; Kiss *et al.*, 1994), THCS, (Dillmann 1990; Wong *et al.*, 2011). There are also some reports concentrating on the role of hyperthyroidism on the atrial fibrillation although the rate of incidence is not large but excess thyroid hormone, on heart can be followed with adverse clinical presentation, among them including atrial fibrillation and ventricular dysfunction (Roffi *et al.*, 2005; Fadel *et al.*, 2000; Hendriksen and Petersen, 1995; Dahl *et al.*, 2008; Brandt *et al.*, 2011; Kaminski *et al.*, 2012; Dillmann, 1990; Klein 1990; Forfar *et al.*, 1982; Klein and Ojamaa, 1998).

In general excess T4 and T3 eventually can alter the normal path of heart physiological function therefore it seems many heart diseases can be prevented, if the excess

thyroid hormones of T4 and T3 production and particularly T3 from thyroid gland can be controlled through therapeutic regimens. It seems many undesired heart malfunction possibly can be prevented by treatment of thyroid gland to stop the biosynthesis of extra thyroid hormones (Mansourian, 2010a-c; Fadel *et al.*, 2000; Kaminski *et al.*, 2012; Roffi *et al.*, 2005; Yu and Bilezikian, 2000; Aksnes, 1994), (2,4,8,34, THCS). Klein (1990), Polikar *et al.* (1993), Mintz *et al.* (1991), Klein and Ojamma (1998), Gilligan *et al.* (1996), Feldman *et al.* (1986) and Klein and Ojamma (1998).

Overt hyperthyroidism: Hyperthyroidism clinically is a condition in which thyroid produce elevated amount of thyroid (T4) and triiodothyronine (T3). The metabolic pathways to their production is extensively studied (Mansourian 2010a, b; Mansourian 2011a-c; Dratman and Grodon, 1996; Parma *et al.*, 1995; Emrich *et al.*, 1993).

Thyroid stimulating Hormone (TSH) is a pituitary hormone which after binding to its receptor on thyroid and producing cyclic adenosine monophosphate (cAMP) biochemical process within the thyrocyte membrane is occurred and adenylate cyclase is activated. The latter enzyme is responsible for the production of cAMP from adenosine triphosphate (ATP). In euthyroid subject there is a correlation between the production of thyroid hormones T4, T3 and TSH, based on the thyroid hormone reference range defined from the laboratory thyroid hormone kit guidelines (Cooper, 2003; Karger and Fuherer, 2008; Dratman and Grodon, 1996; Persani *et al.*, 2000; Karger and Fuherer, 2008; Bogazzi *et al.*, 1999; Shahmohammadi *et al.*, 2008; Mansourian *et al.*, 2010a, b, e; Mansourian *et al.*, 2011; Mansourian and Ahmadi, 2010; Mansourian *et al.*, 2010a; Mansourian, 2011a, b, 2012; Studer and Ramelli, 1982; Studer *et al.*, 1989; Bogazzi *et al.*, 1999; Kinney *et al.*, 1988). As thyroid gland begin to synthesis elevated amount of T4 and T3. The TSH concentration suppressed due to negative correlation between thyroid hormones of T4, T3 and TSH. It is widely believed that thyroid hormone mainly positively interfere with various metabolic pathways and during healthy state, human thyroid gland produce, a steady thyroid hormone required for normal physiological concentration. In case of elevated concentration of T4 and T3, are occurred due to various factors, it will be associated with signs and syndromes well known as thyrotoxicosis. The clinical manifestation accompanied with thyrotoxicosis are many including heart abnormality, weight loss, anxiety, nervous system disorders, psychological abnormalities, heat resistance, muscle disorders, gastrointestinal abnormality, skin disorders are among the clinical disorders of hyperthyroidism, also the

suppression of thyroid hormones which originated from many disorders and other multi-factorial cases and may cause the reverse scenario of hyperthyroidism should also be taken into consideration (Cooper, 2003; Persani *et al.*, 2000; Mansourian, 2010a; Nayak and Burman, 2006; Shimatsu *et al.*, 1999; Mansourian *et al.*, 2008; Mansourian, 2010b, e, f). The physiological and environmental changes among them nutritional malfunction and other physiological cases including pregnancies and metabolic and non metabolic disorders and the therapeutic regimens and possible other interferences must be under surveillance for the proper management of heart -thyroid hormones related diseases (Waring *et al.*, 2012; Mansourian *et al.*, 2007; Mansourian, 2011c, d, f; Rendon, 2005, Tajik and Nazifi, 2011; Franklyn and Gammage, 2007; Mansourian, 2010f; Mansourian *et al.*, 2008; Rendon, 2005; Tajik and Nazifi, 2011; McGrowder *et al.*, 2006).

The heart disorders originated from thyrotoxicosis include increasing heart beat and output, in which is greatly irrespective of the metabolic rate (Brandt *et al.*, 2011; Kim *et al.*, 2011; Mansourian, 2012; DeGroot and Leonard, 1970) although, thyrotoxicosis can cause heart abnormality by itself (Levine and Sturgis, 1924; Likoff and Levine, 1943) but also it can further disrupt and badly manipulate, the heart disorder which was already present. (Brandt *et al.*, 2011; Sandler and Wilson, 1959, Summer and Surleas, 1961; Ikram, 1985; Magner *et al.*, 1988). Thyrotoxicosis play a fundamental modification role on cardiovascular system resulting in the elevation of basic metabolic rate, with undesired blood circulation and increased blood volume to the extent that heart normal physiological pathway is altered (Makino *et al.*, 2012; DeGroot and Leonard, 1970; Chaudhury *et al.*, 1987; Kim *et al.*, 1987).

Heart and hyperthyroidism: It seem there are a close metabolic pathways between the function of excess thyroid hormones and extra adrenaline and noradrenalin and it seem possible, that thyroid hormone and catecholamine elevation have a simultaneous package on heart function and these two system behave on heart physiological process. There are some hints in literature that the thyroid hormones elevation enhance the biological activity of adrenaline and noradrenalin, it is also reported that (Kim *et al.*, 2011; Mansourian, 2010a; Roffi *et al.*, 2005; Fadel *et al.*, 2000; Karger and Fuherer, 2008; Persani *et al.*, 2000; Cooper, 2003; Levey and Klein, 1990).

As it was mentioned earlier the main function of T4 and T3 on heart muscle is through the gene expression elevation with subsequent protein production including,

those protein located on the cell surface mainly named receptors including catecholamine receptor on the myocytes. Some reports indicate, the over activity of heart muscle following thyrotoxicosis is due to direct action of thyroid hormone in synthesising elevated amount of adrenaline and noradrenaline receptor on myocytes with the subsequent elevatory action of catecholamines, on the heart muscle (Mansourian 2011a; Makino *et al.*, 2012; Mansourian, 2010f; Levey and Klein, 1990; Mansourian, 2010e).

The combined effect of thyroid hormones and catecholamine on the heart function, resulted into the elevation of blood volume, which take place by over-load of heart function much higher than its normal physiological capacity with subsequent heart failure which can be reversed following thyroid returning to normal function following medical treatments (Franklyn and Gammage, 2007; Kannel *et al.*, 1998; Kim *et al.*, 1987; Forfar *et al.*, 1982). Thyroid hormones excess and eventual heart failures which is accompanied with thyrotoxicosis not only lead to heart hypertrophy which is eventually directed to increasing systolic contractibility and diastolic relaxation but also ends up with, atrial fibrillation (Levy, 2002; Forfar *et al.*, 1979; Monreal *et al.*, 1988; Staffurth *et al.*, 1977; Sandler and Wilson, 1959; Summers and Surtees, 1961; Ikram, 1985; Magner *et al.*, 1988; Levine and Sturgis, 1924; Likoff and Levine, 1943).

The mechanism behind biochemical effect of T4 and T3 on atrial fibrillation also is not fully understood but hyperthyroidism interfere with proper function of atrial pathway within the heart muscle (Sandler and Wilson, 1959; Summers and Surtees, 1961; Ikram, 1985; Levine and Sturgis, 1924; Likoff and Levine, 1943; DeGroot and Leonard, 1970; Freedberg *et al.*, 1970).

How thyrotoxicosis affect the heart: It seems palpitation is among the signs which in some occasion is clinically manifest itself with thyrotoxicosis. Although, there are an interrelation ship metabolic pathways between central nervous system and thyroid in respect to heart myocytes behavior but it is widely believed that, heart beat can be elevated among thyrotoxic patients even when they receive B-blocker to inhibit the function of catecholamines (Cacciatori *et al.*, 1996).

Although, there are not a clear-cut rate of incidence of heat atrial fibrillation among subjects with thyrotoxicosis but it is widely believed that about 5-22% of patients with thyrotoxicosis may have the clinical manifestation of atrial fibrillation but the same heart disorder among non-thyrotoxic patients is reported to be less than even 1% (Sandler and Wilson, 1959; Summers and Surtees, 1961; Ikram, 1985; Levine and

Sturgis, 1924; Likoff and Levine, 1943; DeGroot and Leonard, 1970; Freedberg *et al.*, 1970; Iwasaki *et al.*, 1989; Petersen and Hansen, 1988; Ostrander *et al.*, 1965; Nordyke *et al.*, 1988).

It seems T3 related thyrotoxicosis is much more potent in causing heart disorder (Ostrander *et al.*, 1965).

The prevalence of atrial fibrillation is higher among quarter of older in general population of male and female of more than sixty years of age (Hak *et al.*, 2000; Mitrou *et al.*, 2011; Mansourian *et al.*, 2010a).

Although, heart disorders and among them atrial fibrillation presentation can be considered as a common clinical manifestation of thyrotoxicosis but this area of investigation is not clearly cut and defined elaboration about the role of excess thyroid hormone on atrial fibrillations are not properly understood and the findings, in this area of research are shaky and even with laboratory measurements of thyroid related hormone of TSH, T4 and T3 and subsequent comparison of these latter hormones with the manifestation of atrial fibrillation, one can get not proper understanding and is not able to comment clearly on a precise overlook in this area of thyroid-heart pathophysiology (Kannel *et al.*, 1998; Levy, 2002; Hendriksen and Petersen, 1995; Hurley *et al.*, 1981; Giladi *et al.*, 1991; Tajiri *et al.*, 1986; Davis *et al.*, 1985; Forfar *et al.*, 1979; Forfar *et al.*, 1979; Staffurth *et al.*, 1977).

Thyrotoxicosis manipulate heart ventricular: Hyperthyroidism is associated with cardiovascular disorders which in some cases leading to mortalities. It is reported that the Left Ventricular Hypertrophy (LVH) may be the major risk factor for the mortality in subjects affiliated with thyrotoxicosis. There are various reports indicating thyrotoxicosis adversely affect heart function and it may eventually cause the disorder on the LVH. There are documented reports on the role of thyroid hormone on the physio-pathological behavior of heart function and as it was already mentioned thyrotoxicosis may eventually disrupt the normal physiological pathway of cardiovascular system including the elevation of myocyte contraction (Henderson *et al.*, 2009; Diao *et al.*, 1998; Little *et al.*, 1990; Taillard *et al.*, 2011; Yue *et al.*, 2011; Bird-Lake, 2011).

The reduction of myocyte and vascular resistance, an increase in the level of heart output, the disruption of heart beat arrhythmias including sinus tachycardia atrial and ventricular disorders and eventually atrial fibrillation can be among the abnormality with hyperthyroidism and its eventual clinical manifestation well known as thyrotoxicosis (Chen *et al.*, 2006; Kaminski *et al.*, 2012).

It seems that thyroid hormone function tests which are carried out by medical diagnostic laboratory are the

key factors in labeling the hyper thyroid patients, hyperthyroidism defined when TSH is suppressed lower than reference range of laboratory manual kit but with elevated thyroid hormones of either T4, T3 or both hormones (Mansourian 2010a, b; Toils *et al.*, 1978; Emerson and Utiger, 1972; Emrich *et al.*, 1993; Studer and Ramelli, 1982; Karger and Fuherer, 2008; Cooper, 2003; Persani *et al.*, 2000; Nayak and Burman, 2006; Maji, 2006; Makino *et al.*, 2012; Shahmohammdi *et al.*, 2008; Mansourian and Ahmadi, 2010). The overt hyperthyroidism which is associated with suppressed TSH and elevated T4 and T3 may clinically accompanied with clinical manifestation collectively known as thyrotoxicosis. The elevated T4, T3 and particularly T3 in case of heart can have an adverse side effects on the heart muscle and vascular system. Thyrotoxicosis may eventually end up with fatal scenario. Left ventricular hypertrophy is one of serious fatal conditions among the adverse effects of excess thyroid hormone in this area of cardiovascular pathophysiology are thoroughly investigated (Kim *et al.*, 2011; Mansourian, 2012; Kannel and Cobb, 1992; Haider *et al.*, 1998; Shirani *et al.*, 1993; Kobori *et al.*, 1999; Petretta *et al.*, 2001; Degens *et al.*, 2003; Hu *et al.*, 2003; Donatelli *et al.*, 2003).

It is believed LVH itself independently of other cause of cardiovascular disorders have a fatal outcome for the heart muscle and vascular diseases including atherosclerosis, heart failure, ventricular irregularities and unpredicted death due to cardiovascular disorders (Little *et al.*, 1990; Bird-Lake, 2011; Diao *et al.*, 1998; Taillard *et al.*, 2011; Roffi *et al.*, 2005; Schmidt-Ott and Ascheim, 2006 ; Makino *et al.*, 2012; Mansourian, 2010d; Mansourian *et al.*, 2008; Kannel and Cobb, 1992; Haider *et al.*, 1998).

Also it seems that thyrotoxicosis proved to be mainly responsible for many from of cardiovascular disease including left ventricular hypertrophy and eventual fatal outcome also there are some argument and controversial discussions about the definition of hyperthyroidism from laboratory point of view. These latter studies indicated and concentrate on the laboratory findings of TSH and argued that at some period the suppressed TSH level and cardiovascular disorder particularly LVH may not have direct correlation (Mansourian *et al.*, 2007; Parle *et al.*, 2001; Tunbridge *et al.*, 1977; Hollowell *et al.*, 2002). In my opinion the thyroid function can only be assessed only after careful examination of TSH, T4, T3 and following determination of all of three hormones and examination of thyroid hormone receptor only at that time one can label for sure, the hyperthyroid patient precisely. Therefore arguments about the nutritional status of one society including the iodine status do not help in the argument

about the adverse effect of thyrotoxicosis on the cardiovascular system (Mansourian, 2011a; Mansourian *et al.*, 2007; Mansourian, 2011b; Makino *et al.*, 2012; Tunbridge *et al.*, 1977; Hollowell *et al.*, 2002). One other careful consideration in this area of research is the therapeutic drug regiment which can possibly interfere with available data and poised itself for possible misdiagnosis in the management of thyrotoxic heart diseases (Franklyn and Gammage, 2007; Wong *et al.*, 2011; Mansourian, 2012; Mansourian 2010a, f).

Studies indicated it seems that LVH incidence among general population to be about 10% but the same index for LVH for thyrotoxic patients is more than 5 times of general population (Little *et al.*, 1990; Taillard *et al.*, 2011; Roffi *et al.*, 2005; Schmidt-Ott and Ascheim, 2006; Hak *et al.*, 2000). Various other studies are in agreement with the adverse effects of thyrotoxicosis on the cardiovascular functions including LVH (Biondi *et al.*, 1996; Biondi *et al.*, 1993; Dillmann, 1990; Kinugawa *et al.*, 2001).

Also the roll of excess thyroid hormone on the malfunction of cardiovascular, system is well documented, other related factors including older age, obesity and increased body mass index and pulse pressure abnormalities in absence excess thyroid hormone can also separately play the key roles on the initiation of LVH with T4 and T3 intervention (Waring *et al.*, 2012; Kaminski *et al.*, 2012; Kannel and Cobb, 1992; Coca *et al.*, 1999; Schirmer *et al.*, 1999). In according to earlier findings, it seems that women are more prone to LVH, due to higher incidence of hyperthyroidism among female population and other possible factors in this regards, also this argument is not universally agreed on (Mansourian, 2012; Mansourian *et al.*, 2008, 2010a; Mansourian, 2010a, b, e, f; Coca *et al.*, 1999; Schirmer *et al.*, 1999).

Although, LVH seems to be the main complication in thyrotoxicosis but there are reports indicating the Right Ventricular Systolic Dysfunction (RVSD) also can be considered one of the adverse effect of hyperthyroidism.

There are documented report which demonstrate the cardiovascular lesion associated with thyrotoxicosis mainly related to LVH but as it was mentioned earlier, it seems there are heart malfunction, which effect both LVH and RVSD (Weissel, 2001; Raddino *et al.*, 2001; Di Giovambattista, 2008; Dahl *et al.*, 2008; Klein and Ojamma, 2001; Umana *et al.*, 2003; Siu *et al.*, 2007; Di Giovambattista, 2008).

There are other studies indicating that RVSD can be considered as an independent and isolated cardiac disorder and it is not certain whether should the LVH and

RVSD malfunction happen on the same time when thyrotoxicosis adversely effect cardiovascular system (Dahl *et al.*, 2008; Simko *et al.*, 2004; Kaminski *et al.*, 2012; Chen *et al.*, 2006; Kaminski *et al.*, 2012; Nadkarni *et al.*, 2008; Lozano and Sharma, 2004; Cohen and Schattner, 2003; Park *et al.*, 2006; Lozano and Sharma, 2004; Nakchbandi *et al.*, 1999; Syriou *et al.*, 2008).

As it was mentioned the right ventricular RVD, does play a major risk factor for the heart failure, right and left ventricular dysfunction not necessarily happen parallel to each other (Dahl *et al.*, 2008; Cohen and Schattner, 2003; Park *et al.*, 2006; Lozano and Sharma, 2004; Nakchbandi *et al.*, 1999; Syriou *et al.*, 2008; Kang *et al.*, 2009).

Although, it seems the thyrotoxic side effect of thyroid hormone on the muscle cells are adequately established in causing the elevation of heart rate, left ventricular dysfunction lowering vascular resistance enhancing Sodium re-absorption and elevating the production of hormone responsible for blood cell formation but the metabolic pathway to the RVD in cardiovascular system during hyperthyroidism, does play a different path compared to the former signs and systems within the cardiovascular system (Schmidt-Ott and Ascheim, 2006; Bird-Lake, 2011; Raddino *et al.*, 2001; Di Giovambattista, 2008; Nadkarni *et al.*, 2008; Dahletal.,2008; Kleinand Ojamma, 2001; Pereira *et al.*, 2000; Kwak *et al.*, 2004; Kiss *et al.*, 1994).

How atrial fibrillation can be affected by thyrotoxicotic:

Atrial Fibrillation (AF) is a thyrotoxicotic related malfunction, take place through ionized calcium irregularity within myocytes with eventual heart dysfunction (Hurley *et al.*, 1981; Kannel *et al.*, 1998; Bielecka-Dabrowa *et al.*, 2009; Dahl *et al.*, 2008; Klein and Ojamma, 2001; Umana *et al.*, 2003). On condition that thyrotoxicosis persist for enough period of time can effectively cause atrial fibrillation which can be associated with LVD. The combination of atrial fibrillation, Sinus tachycardia and left ventricular dysfunction, consequently lead to tachycardia with eventual disorders in the heart physiology causing the pathological disturbance of heart muscle (Levy, 2002; Monreal *et al.*, 1988; Raddino *et al.*, 2001; Di Giovambattista, 2008; Umana *et al.*, 2003; Siu *et al.*, 2007). As Atrial fibrillation is a condition with eventual fatal scenario due to heart beat disturbance which may induce blood coagulation with the cardiac itself with subsequent fatal picture of cardiovascular system (Diao *et al.*, 1998; Forfar *et al.*, 1979; Staffurth *et al.*, 1977; Banach *et al.*, 2007a; Mariscalco *et al.*, 2008; Staffurth *et al.*, 1977). It seems excess thyroid hormone in some subjects which are prone

to hyperthyroidism lead to atrial fibrillation and the incidence of atrial fibrillation among thyrotoxic patients, are greater than non-thyrotoxic subjects within the normal society and it seems is more common among male hyperthyroid patients, particularly T3 type of thyrotoxicosis. Atrial fibrillation is a heart malfunction directly related to chronological age, various cardiac, vascular and some other disorders Excess thyroid hormone reduce the action potential which can be considered as pre-existing risk factor for the clinical manifestation of atrial fibrillation (Kaminski *et al.*, 2012; Yue *et al.*, 2011; Kannel *et al.*, 1998; Banach *et al.*, 2007b; Mariscalco *et al.*, 2008; Staffurth *et al.*, 1977). Atrial fibrillation is disorder may clinically presented with thyrotoxicosis and usually can be followed by fatal outcome, mainly due to embolism (Hurley *et al.*, 1981; Elie *et al.*, 2011; Hendriksen and Petersen, 1995; Bielecka-Dabrowa *et al.*, 2009; Staffurth *et al.*, 1977) and atrial fibrillation may also occur among non- thyroidal disease and normal subjects but thyrotoxicosis aggravate the onset of atrial fibrillation. As it was mentioned earlier, atrial fibrillation is not usually symptom of younger age but patient of more than sixty years of age are more afflicted to atrial fibrillation The age related arrhythmia associated with atrial fibrillation might be lowered among thyrotoxic patient, compared to general population. (Mitrou *et al.*, 2011; Hak *et al.*, 2000; Levy, 2002; Kaminski *et al.*, 2012; Chen *et al.*, 2006; Weissel, 2001; Agner *et al.*, 1984; Mohacsi *et al.*, 1990). In a separate study it was found that hyperthyroidism alone based on thyroid hormone measurement can not be a key factor for atrial fibrillation. Cardiovascular disorders and the excess thyroid hormones of T4 and particularly T3 should be carried out for enough period of time to be able to manifest the whole picture of thyrotoxicosis and only on that time atrial fibrillation can be clinically established and manifest itself (Roffi *et al.*, 2005; Wong *et al.*, 2011; Fadel *et al.*, 2000; Staffurthetal., 1977; Krahn *et al.*, 1996). There are various reports showing in majority of cases with atrial fibrillation, the abnormality can be corrected following thyrotoxic treatment, also this reversion to healthy state is mostly depended to the duration of atrial fibrillation onset and the thyrotoxic severity and patient age (Yue *et al.*, 2011; Dahl *et al.*, 2008; Northcote *et al.*, 1986; Banach *et al.*, 2008; Shimizu *et al.*, 2002), therefore those subjects with atrial fibrillation of older than sixty years of age should be evaluated for thyroid hormone test through the careful laboratory measurement of suspected person serum to eliminate the possibility of hyperthyroidism for cardiovascular diseases (Mansourian *et al.*, 2010a; Mansourian 2010b, c, e; Shahmohammdi *et al.*, 2008; Northcote *et al.*, 1986;

Banach *et al.*, 2008; Shimizu *et al.*, 2002; Nakazawa *et al.*, 1982). The laboratory examination of thyroid function test should include TSH, T4, T3 and the measurement of TSH alone without the assessment of T4 and T3 can be misleading in the assessment of thyrotoxic patients and as result of this mistake the cardiovascular diseases related to thyroid abnormality is occasionally miss-interpreted and undetected cardiovascular related thyrotoxic patients might loose the proper pathway to clinical care to recover from heart dysfunctions (Mansourian, 2010a, 2012; Staffurth *et al.*, 1977; Nakazawa *et al.*, 1982; Forfar *et al.*, 1981; Banach *et al.*, 2007a; Arns *et al.*, 2005).

CONCLUSION

- Thyroid hormones and particularly T3 stimulate the heart myocyte at nuclear level, with subsequent gene expression of particular proteins within the heart cells and producing the proteins which are required for the heart function
- There are various reports in this area of heart physiology indicating any disruption in the amount of thyroid hormones seriously modify heart function adversely, due to disruption in the amount of required proteins responsible for the proper function of heart physiology
- Thyroid hormone and particularly T3 stimulate the production of Calcium-ATPase, which is an enzyme responsible for active relocation of ionized calcium (Ca²⁺) into myocytes sarcoplasmic reticulum and it is the vital factor for the critical physiological pathways of myocytes, namely known as systolic diastolic function of the heart
- Hyperthyroidism is associated with cardiovascular disorders which in some cases leading to mortalities. Thyrotoxicosis is a term given for the clinical manifestation of hyperthyroidism which can invoke heart and vascular dysfunction through the mechanism at myocyte nuclear level
- Thyrotoxicosis can be considered as risk factor for heart disorders including Atrial Fibrillation (AF), Left Ventricular Hypertrophy (LVH), Right Ventricular Systolic Dysfunction (RVSD)
- It is also reported that the Left Ventricular Hypertrophy (LVH) may be considered the major risk factor for the mortality in subjects affiliated with thyrotoxicosis
- Atrial fibrillation abnormality, can be considered as clinical manifestation of thyrotoxicosis. Atrial fibrillation is considered as a risk factor for embolism and the incidence of cardiovascular disorders commonly higher among thyrotoxic patients

- To Avoid any miscalculation of heart dysfunctions the thyrotoxicosis in cardiovascular patients should be checked through careful measurements T4 and T3 to exclude any thyroid hormone-related heart diseases, by doing that any miss-interpretation and miss-diagnosis of undetected thyrotoxic patients with heart dysfunctions are prevented
- As heart failure is age dependent the thyroid function tests should be carried out for all subjects over sixty of years to exclude heart dysfunction due to possible hyperthyroidism

REFERENCES

- Agner, T., T. Almdal, B. Thorsteinsson and E. Agner, 1984. A reevaluation of atrial fibrillation in thyrotoxicosis. *Dan Med. Bull.*, 31: 157-159.
- Aksnes, H., 1994. Heart failure and convulsions in thyrotoxicosis. A young woman with Graves disease. *TidsskrNor Laegeforen*, 114: 2954-2955.
- Arns, D., O. Maden, O. Ozdemir, S. Arns and S. Topaloglu *et al.*, 2005. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. *Int. J. Cardiol.*, 99: 59-64.
- Banach, M., A. Goch, M. Misztal, J. Rysz, R. Jaszewski and J.H. Goch, 2007a. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. *J. Thoracic Cardiovasc. Surg.*, 134: 1569-1576.
- Banach, M., M. Misztal, A. Goch, J. Rysz and J.H. Goch, 2007b. Predictors of atrial fibrillation in patients following isolated surgical revascularization. A metaanalysis of 9 studies with 28 786 patients. *Arch. Med. Sci.*, 3: 229-239.
- Banach, M., G. Mariscalco, M. Ugurlucan, D.P. Mikhailidis, M. Barylski and J. Rysz, 2008. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery. Preoperative atrial fibrillation-still underestimated opponent. *Europace*, 10: 1266-1270.
- Bielecka-Dabrowa, A., D.P. Mikhailidis, J. Rysz and M. Banach, 2009. The mechanisms of atrial fibrillation in hyperthyroidism. *Thyroid Res.*, Vol. 2, No. 1. 10.1186/1756-6614-2-4.
- Biondi, B., S. Fazio, C. Carella, G. Amato and A. Cittadini *et al.*, 1993. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. *J. Clin. Endocrinol. Metab.*, 77: 334-338.

- Biondi, B., S. Fazio, C. Carella, D. Sabatini and G. Amato *et al.*, 1994. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. *J. Clin. Endocrinol. Metab.*, 78: 1028-1033.
- Biondi, B., S. Fazio, A. Cuocolo, D. Sabatini and E. Nicolai *et al.*, 1996. Impaired cardiac reserve and exercise capacity in patients receiving long term thyrotropin suppressive therapy with levothyroxine. *J. Clin. Endocrinol. Metab.*, 81: 4224-4228.
- Bird-Lake, E., 2011. Severe transient left ventricular dysfunction induced by thyrotoxicosis. *Neth. Heart J.*, 19: 352-354.
- Bogazzi, F., L. Bartalena, S. Brogioni, A. Burelli and L. Manetti *et al.*, 1999. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: Studies *in vivo* by color flow Doppler sonography. *Eur. J. Endocrinol.*, 140: 452-456.
- Brandt, F., A. Green, L. Hegedus and T.H. Brix, 2011. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. *Eur. J. Endocrinol.*, 165: 491-497.
- Brent, G.A., 1994. The molecular basis of thyroid hormone action. *N. Engl. J. Med.*, 331: 847-853.
- Cacciatori, V., F. Bellavere, A. Pezzarossa, A. Dellera and M.L. Gemma *et al.*, 1996. Power spectral analysis of heart rate in hyperthyroidism. *J. Clin. Endocrinol. Metab.*, 81: 2828-2835.
- Chaudhury, S., F. Ismail-Beigi, G.G. Gick, R. Levenson and I.S. Edelman, 1987. Effect of thyroid hormone on the abundance of Na, K-adenosine triphosphatase α -subunit messenger ribonucleic acid. *Mol. Endocrinol.*, 1: 83-89.
- Chen, J.L., H.W. Chiu, Y.J. Tseng and W.C. Chu, 2006. Hyperthyroidism is characterized by both increased sympathetic and decreased vagal modulation of heart rate: Evidence from spectral analysis of heart rate variability. *Clin. Endocrinol.*, 64: 611-616.
- Coca, A., R. Gabriel, M. de la Figuera, J.L. Lopez-Sendon and R. Fernandez *et al.*, 1999. The impact of different echocardiographic diagnostic criteria on the prevalence of left ventricular hypertrophy in essential hypertension: The VITAE study. *J. Hypertens.*, 17: 1471-1480.
- Cohen, J. and A. Schattner, 2003. Right heart failure and hyperthyroidism: A neglected presentation. *Am. J. Med.*, 115: 76-77.
- Cooper, D.S., 2003. Hyperthyroidism. *Lancet*, 362: 459-468.
- Dahl, P., S. Danzi and I. Klein, 2008. Thyrotoxic cardiac disease. *Curr. Heart Failure Rep.*, 5: 170-176.
- Davis, P.J. and F.B. Davis, 1993. Acute cellular actions of thyroid hormone and myocardial function. *Ann. Thoracic Surg.*, 56: S16-S23.
- DeGroot, W.J. and J.J. Leonard, 1970. Hyperthyroidism as a high cardiac output state. *Am. Heart J.*, 79: 265-275.
- Degens, H., A. Gilde, M. Lindhout, P. Willemsen, G. Van der Vusse and M. Van Bilsen, 2003. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. *Am. J. Physiol. Heart Circ. Physiol.*, 284: H108-H115.
- Di Giovambattista, R., 2008. Hyperthyroidism as a reversible cause of right ventricular overload and congestive heart failure. *Cardiovasc. Ultrasound*, Vol. 6. 10.1186/1476-7120-6-29.
- Diao, M., A. Kane, I.B. Diop, M. Sarr, S.A. Ba and S.M. Diouf, 1998. Cardiac thyrotoxicosis and left ventricular thrombosis, a case report. *Dakar Med.*, 43: 243-244.
- Dillmann, W.H., 1990. Biochemical basis of thyroid hormone action in the heart. *Am. J. Med.*, 88: 626-630.
- Donatelli, M., P. Assennato, V. Abbadi, M.L. Bucalo and V. Compagno *et al.*, 2003. Cardiac changes in subclinical and overt hyperthyroid women: Retrospective study. *Int. J. Cardiol.*, 90: 159-164.
- Dratman, M.B. and J.T. Grodon, 1996. Thyroid hormones as neurotransmitter. *Thyroid*, 6: 639-647.
- Emerson, C.H. and R.D. Utiger, 1972. Hyperthyroidism and excessive thyrotropin secretion. *N. Engl. J. Med.*, 287: 328-333.
- Emrich, D., U. Erlenmaier, M. Pohl and H. Luig, 1993. Determination of the autonomously functioning volume of the thyroid. *Eur. J. Nucl. Med. Mol. Imaging*, 20: 410-414.
- Everts, M.E., F.A. Verhoeven, K. Bezstarosti, E.P. Moorings, G. Hennemann, T.J. Visser and J.M. Lamers, 1996. Uptake of thyroid hormone in neonatal rat cardiac myocytes. *Endocrinology*, 137: 4235-4242.
- Fadel, B.M., S. Ellahham, J. Lindsay Jr., MD. Ringel, L. Wartofsky and K.D. Burman, 2000. Hyperthyroid heart disease. *Clin. Cardiol.*, 23: 402-408.
- Feldman, T., K.M. Borow, D.H. Same, A. Neumann and R.M. Lang, 1986. Myocardial mechanics in hyperthyroidism: Importance of left ventricular loading conditions, heart rate and contractile state. *J. Am. Coll. Cardiol.*, 7: 967-974.
- Forfar, J.C., H.C. Miller and A.D. Toft, 1979. Occult thyrotoxicosis: A correctable cause of idiopathic atrial fibrillation. *Am. J. Cardiol.*, 44: 9-12.
- Forfar, J.C., C.M. Feek, H.C. Miller and A.D. Toft, 1981. Atrial fibrillation and isolated suppression of the pituitary-thyroid axis: Response to specific antithyroid therapy. *Int. J. Cardiol.*, 1: 43-48.

- Forfar, J.C., AL. Muir, S.A. Sawers and AD. Toft, 1982. Abnormal left ventricular function in hyperthyroidism: Evidence for a possible reversible cardiomyopathy. *N. Engl. J. Med.*, 307: 1165-1170.
- Franklyn, J.A and M.D. Gammage, 2007. Treatment of amiodarone-associated thyrotoxicosis. *Nat. Clin. Pract. Endocrinol. Metab.*, 3: 662-666.
- Freedberg, AS., J.G. Papp and E.M.V. Williams, 1970. The effect of altered thyroid state on atrial intracellular potentials. *J. Physiol.*, 207: 357-369.
- Gick, G.G., J. Melikian and F. Ismail-Beigi, 1990. Thyroidal enhancement of rat myocardial Na, K-ATPase: Preferential expression of $\alpha 2$ activity and mRNA abundance. *J. Membr. Biol.*, 115: 273-282.
- Giladi, M., D. Aderka, L. Zeligman-Melatzki, A Finkelstein, D. Ayalon and Y. Levo, 1991. Is idiopathic atrial fibrillation caused by occult thyrotoxicosis? A study of one hundred consecutive patients with atrial fibrillation. *Int. J. Cardiol.*, 30: 309-313.
- Gillebert, T.C., AF. Leite-Moreira and S.G. De Hert, 2000. Load dependent diastolic dysfunction in heart failure. *Heart Failure Rev.*, 5: 345-355.
- Gilligan, D.M., K.A. Ellenbogen and AE. Epstein, 1996. The management of atrial fibrillation. *Am. J. Med.*, 101: 413-421.
- Graettinger, J.S., J.J. Muenster, L.A. Selverstone and I.A. Campbell, 1959. A correlation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure. *J. Clin. Invest.*, 38: 1316-1327.
- Haider, A, M. Larson, E. Benjamin and D. Levy, 1998. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. *J. Am. Cardiol.*, 32: 1454-1459.
- Hak, AE., HAP. Pols, T.J. Visser, H.A. Drexhage, A Hofman and J.C.M. Witteman, 2000. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The rotterdam study. *Ann. Intern. Med.*, 132: 270-278.
- Henderson, K.K., S. Danzi, J.T. Paul, G. Leya, I. Klein and AM. Samarel, 2009. Physiological replacement of T₃ improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. *Circ. Heart Failure*, 2: 243-252.
- Hendriksen, O. and C.L. Petersen, 1995. Embolic episodes after treatment of atrial fibrillation in a patient with thyrotoxicosis. *Ugeskr Laeger*, 157: 4138-4139.
- Hollowell, J.G., N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer and L.E. Braverman, 2002. Serum TSH, T4 and thyroid antibodies in the United States population (1988 to 1994): National health and nutrition examination survey (NHANES III). *J. Clin. Endocrinol. Metab.*, 87: 489-499.
- Hu, L.W., L.A. Benvenuti, E.A. Liberti, M.S. Cameiro-Ramos and M.L.M. Barreto-Chaves, 2003. Thyroxine-induced cardiac hypertrophy: Influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. *Am. J. Physiol.*, 285: R1473-R1480.
- Hurley, D.M., AN. Hunter, M.J. Hewett and J.R. Stockigt, 1981. Atrial fibrillation and arterial embolism in hyperthyroidism. *Aust. N. Z. J. Med.*, 11: 391-393.
- Ikram, H., 1985. The nature and prognosis of thyrotoxic heart disease. *Q. J. Med.*, 54: 19-28.
- Iwasaki, T., M. Naka, K. Hiramatsu, T. Yamada and A. Niwa *et al.*, 1989. Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves disease. *Cardiology*, 76: 10-17.
- Kaminski, G.W., K. Makowski, D. Michalkiewicz, J. Kowal, M. Ruchala, E. Szczepanek and G. Gielerek, 2012. The influence of subclinical hyperthyroidism on blood pressure, heart rate variability and incidence of arrhythmia. *Thyroid*, 10.1089/thy.2010-0333 .
- Kang, B., D.K. Cho, K.H. Byun, L.Y. Eun and Y.H. Cho, 2009. Isolated pulmonary arterial hypertension-Janus faces of hyperthyroidism. *Korean Circ. J.*, 39: 168-170.
- Kannel, W.B. and J. Cobb, 1992. Left ventricular hypertrophy and mortality: Results from the Framingham study. *Cardiology*, 81: 291-298.
- Kannel, W.B., P.A. Wolf, E.J. Benjamin and D. Levy, 1998. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: Population-based estimates. *Am. J. Cardiol.*, 82: 2N-9N.
- Karger, S. and D. Fuhrer, 2008. Thyroid storm-thyrotoxic crisis: An Update. *Dtsch. Med. Wochenschr.*, 133: 479-484.
- Kim, D., T.W. Smith and J.D. Marsh, 1987. Effect of thyroid hormone on slow calcium channel function in cultured chick ventricular cells. *J. Clin. Invest.*, 80: 88-94.
- Kim, H.J., T.S. Jung, J.R. Hahm, S.J. Hwang and S.M. Lee *et al.*, 2011. Thyrotoxicosis-induced acute myocardial infarction due to painless thyroiditis. *Thyroid*, 21: 1149-1151.

- Kinney, J.S., E.S. Hurwitz, D.B. Fishbein, P.D. Wolf and P.F. Pinsky *et al.*, 1988. Community outbreak of thyrotoxicosis: Epidemiology, immunogenetic characteristics and long-term outcome. *Am. J. Med.*, 84: 10-18.
- Kinugawa, K., K. Yonekura, R.C. Ribeiro, Y. Eto, S.A. Camacho *et al.*, 2001. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. *Circ. Res.*, 89: 591-598.
- Kiss, E., A.G. Brittsan, I. Edes, I.L. Grupp, G. Grupp and E.G. Kranias, 1998. Thyroid hormone-induced alterations in phospholamban-deficient mouse hearts. *Circ. Res.*, 83: 608-613.
- Kiss, E.G. Jakab, E.G. Kranias and I. Edes, 1994. Thyroid hormone induced alteration in phospholamban protein expression: Regulatory effects on sarcoplasmic reticulum Ca²⁺ transport and myocardial relaxation. *Circ. Res.*, 75: 245-251.
- Klein, I. and C. Hong, 1986. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. *J. Clin. Invest.*, 77: 1694-1698.
- Klein, I., 1990. Thyroid hormone and the cardiovascular system. *Am. J. Med.*, 88: 631-637.
- Klein, I. and K. Ojamaa, 1998. Thyrotoxicosis and the heart. *Endocrinol. Metab. Clin. North Am.*, 27: 51-62.
- Klein, I. and K. Ojamaa, 2000. The Cardiovascular System in Hypothyroidism. In: Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text, Braverman, L.E. and R.D. Utiger (Eds.). 8th Edn. Lippincott Williams and Wilkins, Philadelphia, PA., USA., pp: 777-782.
- Klein, I. and K. Ojamaa, 2001. Thyroid hormone and the cardiovascular system. *N. Engl. J. Med.*, 344: 501-509.
- Klemperer, J.D., K. Ojamaa and I. Klein, 1996. Thyroid hormone therapy in cardiovascular disease. *Frog. Cardiovasc. Dis.*, 38: 329-336.
- Kobori, H., A. Ichihara, Y. Miyashita, M. Hayashi and T. Saruta, 1999. Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. *J. Endocrinol.*, 160: 43-47.
- Krahn, A.D., G.J. Klein, C.R. Kerr, J. Boone and R. Sheldon *et al.*, 1996. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? *Arch. Internal Med.*, 156: 2221-2224.
- Kwak, J.J., Y.J. Choi, K.H. Kwon and S.H. Park, 2004. A case of myocardial stunning in hyperthyroidism. *Korean Circ. J.*, 34: 516-519.
- Ladenson, P.W., S.I. Sherman, K.L. Baughman, P.E. Ray and A.M. Feldman, 1992. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. *PNAS*, 89: 5251-5255.
- Levey, G.S. and I. Klein, 1990. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. *Am. J. Med.*, 88: 642-646.
- Levine, S.A. and C.C. Sturgis, 1924. Hyperthyroidism masked as heart disease. *Boston Med. Surg. J.*, 190: 233-237.
- Levy, S., 2002. Atrial fibrillation, the arrhythmia of the elderly, causes and associated conditions. *Anadolu Kardiyol. Derg.*, 2: 55-60.
- Likoff, W.B. and S.A. Levine, 1943. Thyrotoxicosis as the sole cause of heart failure. *Am. J. Med. Sci.*, 206: 425-434.
- Little, W.C., T.R. Downes and R.J. Applegate, 1990. Invasive evaluation of left ventricular diastolic performance. *Herz*, 15: 362-376.
- Lozano, H.F. and C.N. Sharma, 2004. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: Case report and review of the literature. *Cardiol. Rev.*, 12: 299-305.
- Magner, J.A., W. Clark and P. Allenby, 1988. Congestive heart failure and sudden death in a young woman with thyrotoxicosis. *West J. Med.*, 149: 86-91.
- Maji, D., 2006. Hyperthyroidism. *J. Indian Med. Assoc.*, 104: 563-564.
- Makino, A., H. Wang, B.T. Scott, J.X.J. Yuan and W.H. Dillmann, 2012. Thyroid Hormone Receptor α and Vascular Function. *Am. J. Physiol. Cell Physiol.*,
- Mansourian, A.R., E.O. Ghaemi, A.R. Ahmadi, A. Saifi, A.V. Moradi and S. Bakhshandeh-Nosrat, 2007. A survey of urinary iodine concentration in South-east of Caspian Sea in Northern, Iran. *Pak. J. Biol. Sci.*, 10: 2166-2171.
- Mansourian, A.R., E. Ghaemi, A.R. Ahmadi, A. Marjani, A. Saifi and S. Bakhshandehnosrat, 2008. Serum lipid level alterations in subclinical hypothyroid patients in Gorgan (South East of Caspian Sea). *Chinese Clin. Med.*, 3: 206-210.
- Mansourian, A.R., 2010a. A review on hyperthyroidism: Thyrotoxicosis under surveillance. *Pak. J. Biol. Sci.*, 13: 1066-1076.
- Mansourian, A.R., 2010b. A review on post-puberty Hypothyroidism: A glance at myxedema. *Pak. J. Biol. Sci.*, 13: 866-876.
- Mansourian, A.R., 2010c. Metabolic pathways of tetraiodothyronine (T₄) and triiodothyronine (T₃) production by thyroid gland: A review of articles. *Pak. J. Biol. Sci.*, 14: 1-12.
- Mansourian, A.R., 2010d. The immune system which adversely alter thyroid functions: A review on the concept of autoimmunity. *Pak. J. Biol. Sci.*, 13: 765-774.

- Mansourian, A.R., 2010e. The state of serum lipids profiles in sub-clinical hypothyroidism: A review of the literature. *Pak. J. Biol. Sci.*, 13: 556-562.
- Mansourian, A.R., 2010f. Thyroid function tests during first-trimester of pregnancy: A review of literature. *Pak. J. Biol. Sci.*, 13: 664-673.
- Mansourian, A.R and AR Ahmadi, 2010. Correlation between inverse age and serum thyroxine level among children and adolescents. *J. Clin. Diagn. Res.*, 4: 3196-3200.
- Mansourian, A.R, A.R Ahmadi, A. Saifi and S. Bakhshandehnosrat, 2010a. The children reference range of thyroid hormones in Northern Iran. *Pak. J. Biol. Sci.*, 13: 862-865.
- Mansourian, A.R, A.R Ahmadi, H.R Mansourian, A. Saifi, A. Marjani, G.R Veghari and E. Ghaemi, 2010b. Maternal thyroid stimulating hormone level during the first trimester of pregnancy at the South-East of the Caspian sea in Iran. *J. Clin. Diagn. Res.*, 4: 2472-2477.
- Mansourian, AR, 2011a. Abnormal serum thyroid hormones concentration with healthy functional gland: A review on the metabolic role of thyroid hormones transporter proteins. *Pak. J. Biol. Sci.*, 14: 313-326.
- Mansourian, A.R, 2011b. Central dogma in thyroid dysfunction: A review on structure modification of TSHR as a cornerstone for thyroid abnormalities. *Pak. J. Biol. Sci.*, 14: 170-181.
- Mansourian, AR., 2011c. A review on the metabolic disorders of iodine deficiency. *Pak. J. Biol. Sci.*, 14: 412-424.
- Mansourian, AR, A. Sifi and H.R Mansourian, 2011. Serum thyroxine level during the first-trimester of pregnancy. *J. Clin. Diagn. Res.*, 5: 733-736.
- Mansourian, A.R, 2012. A review on cardiovascular diseases originated from subclinical hypothyroidism. *Pak. J. Biol. Sci.*, 15: 58-67.
- Mariscalco, G., C. Klersy, M. Zanobini, M. Banach and S. Ferrarese *et al.*, 2008. Atrial fibrillation after isolated coronary surgery affects late survival. *Circulation*, 118: 1612-1618.
- McGowder, D., D. Ragoobirsingh and P. Brown, 2006. Therapeutic uses of nitric oxide-donating drugs in the treatment of cardiovascular diseases. *Int. J. Pharmacol.*, 2: 366-373.
- Mintz, G., R Pizzarello and I. Klein, 1991. Enhanced left ventricular diastolic function in hyperthyroidism: Noninvasive assessment and response to treatment. *J. Clin. Endocrinol. Metab.*, 73: 146-150.
- Mitrou, P., SA Raptis and G. Dimitriadis, 2011. Thyroid disease in older people. *Maturitas*, 70: 5-9.
- Mohacsi, A., F. Worum, I. Lorincz, E. Nagy and A. Leovey, 1990. Incidence of rhythm disorders in hyperthyroidism with special respect of old age form. *Acta Med. Hung.*, 47: 21-29.
- Monreal, M., E. Lafoz, M. Foz, A. Sanmarti, I. Salinas, L. Audi and E. Viver, 1988. Occult thyrotoxicosis in patients with atrial fibrillation and an acute arterial embolism. *Angiology*, 39: 981-985.
- Markin, E., 1993. Regulation of myosin heavy chain genes in the heart. *Circulation*, 87: 1451-1460.
- Nadkarni, P.J., M. Sharma, B. Zinsmeister, L. Wartofsky and K.D. Burman, 2008. Thyrotoxicosis-induced ventricular arrhythmias. *Thyroid*, 18: 1111-1114.
- Nakazawa, H.K., K. Sakurai, N. Hamada, N. Momotani and K. Ito, 1982. Management of atrial fibrillation in the post-thyrotoxic state. *Am. J. Med.*, 72: 903-906.
- Nakchbandi, I.A., J.A. Wirth and S.E. Inzucchi, 1999. Pulmonary hypertension caused by Graves thyrotoxicosis: Normal pulmonary hemodynamics restored by (131)I treatment. *Chest*, 116: 1483-1485.
- Nayak, B. and K. Burman, 2006. Thyrotoxicosis and thyroid storm. *Endocrinol. Metab. Clin. North Am.*, 35: 663-686.
- Nordyke, RA., F.I. Gilbert Jr. and A.S.M. Harada, 1988. Graves disease: Influence of age on clinical findings. *Arch. Internal Med.*, 148: 626-631.
- Northcote, R.J., P. MacFarlane, C.M. Kesson and D. Ballantyne, 1986. Continuous 24 h electrocardiography in thyrotoxicosis before and after treatment. *Am. Heart J.*, 112: 339-344.
- Ojamaa, K., J.D. Klemperer, S.S. MacGilvray, I. Klein and A. Samarel, 1996. Thyroid hormone and hemodynamic regulation of beta-myosin heavy chain promoter in the heart. *Endocrinology*, 137: 802-808.
- Ojamaa, K., A. Sabet, A. Kenessey, R. Shenoy and I. Klein, 1999. Regulation of rat cardiac Kvl.5 gene expression by thyroid hormone is rapid and chamber specific. *Endocrinology*, 140: 3170-3176.
- Ojamaa, K., A. Kenessey and I. Klein, 2000. Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. *Endocrinology*, 141: 2139-2144.
- Ostrander Jr., L.D., R.L. Brandt, M.O. Kjelsberg and F.H. Epstein, 1965. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. *Circulation*, 31: 888-898.
- Park, J.H., M.H. Shong, J.H. Lee, S.W. Choi, J.O. Jeoung and I.W. Seang, 2006. Reversible severe tricuspid regurgitation with right heart failure associated with thyrotoxicosis. *Thyroid*, 16: 813-814.

- Park, K.W., H.B. Dai, K. Ojarnaa, E. Lowenstein, I. Klein and F.W. Sellke, 1997. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. *Anesthesia Analgesia*, 85: 734-738.
- Parle, J.V., P. Maissoneuve P, M.C. Sheppard, P. Boyle and I.A. Franklyn, 2001. Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10 year cohort study. *Lancet*, 358: 861-865.
- Parma, J., J. van Sande, S. Swillens, M. Tonacchera, J. Dumont and G. Vassart, 1995. Somatic mutations causing constitutive activation of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas identification of additional mutatuins activating both the cyclic adenosine 3,5-monophosphate and inositol phosphate CA_2+ vascaades. *Mol. Endocrinol.*, 9: 725-733.
- Pereira, N., A. Parisi, G.W. Dec, J. Choo, R. Hajjar and P.C. Gordon, 2000a. Myocardial stunning in hyperthyroidism. *Clin. Cardiol.*, 23: 298-300.
- Persani, L., A. Lania, L. Alberti, R. Romoli and G. Mantovanj *et al.*, 2000b. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. *J. Clin. Endocrinol. Metab.*, 85: 2872-2878.
- Petersen, P. and J.M. Hansen, 1988. Stroke in thyrotoxicosis with atrial fibrillation. *Stroke*, 19: 15-18.
- Petretta, M, D. Bonaduce, L. Spinelli, ML. Vicario and V. Nuzzo *et al.*, 2001. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. *Eur. J. Endocrinol.*, 145: 691-696.
- Polikar, R., A.G. Burger, U. Scherrer and P. Nicod, 1993. The thyroid and the heart. *Circulation*, 87: 1435-1441.
- Raddino, R., T.M. Scarabelli, R. Ferrari, C. Portera, L. Sarasso, A. Fappani and C. Pizzocaro, 2001. Right ventricular heart failure in hyperthyroidism. *Minerva Cardioangiolo.*, 49: 335-341.
- Rendon, D.A., 2005. Mitochondrial cardiac energy metabolism after one treatment with benzonidazole-rochagan®. *Int. J. Pharmacol.*, 6: 623-627.
- Roffi, M., F. Cattaneo and E.J. Topol, 2005. Thyrotoxicosis and the cardiovascular system. *Minerva Endocrinol.*, 30: 47-58.
- Sandler, G. and G.M. Wilson, 1959. The nature and prognosis of heart disease in thyrotoxicosis: A review of 150 patients treated with 131I. *Q. J. Med.*, 28: 347-369.
- Schirmer, H., P. Lunde and K Rasmussen, 1999. Prevalence of left ventricular hypertrophy in a general population: The tromso study. *Eur. Heart J.*, 20: 429-438.
- Schmidt-Oft, UM and DD. Ascheim, 2006. Thyroid hormone and heart failure. *Curr. Heart Foil Rep.*, 3: 114-119.
- Shahmohammdi, F., A.R. Mansourian and H.R. Mansourian, 2008. Serum thyroid hormone level in women with nausea and vomiting in early pregnancy. *J. Med. Sci.*, 8: 507-510.
- Shimatsu, A., H. Murabe, K. Kamoi, Y. Susuki and K. Nakao, 1999. Treatment of thyroptropin secreting pituitary ademomas with octreotide. *Endocr. J.*, 46: 113-123.
- Shimizu, T., S. Koide, J.Y. Noh, K. Sugino, K. Ito and H. Nakazawa, 2002. Hyperthyroidism and the management of atrial fibrillation. *Thyroid*, 12: 489-493.
- Shirani, J., M.M. Barron, M.L. Pierre-Louis and W.C. Roberts, 1993. Congestive heart failure, dilated cardiac ventricles and sudden death m hyperthyroidism. *Am. J. Cardiol.*, 72: 365-368.
- Simko, J., K. Barta, Z. Szabo, E. Varga, E. Nagy and I. Lorincz, 2004. Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone. *Orv. Hetil.*, 145: 2411-2417.
- Siu, C.W., C.Y. Yeung, C.P. Lau, A.W. Kung and H.F. Tse, 2007. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. *Heart*, 93: 483-487.
- Staffurth, J.S., MC. Gibberd and S.N. Fui, 1977. Arterial embolism in thyrotoxicosis with atrial fibrillation. *Bri. Med. J.*, 2: 688-690.
- Studer, H. and F. Ramelli, 1982. Simple goiter and its variants euthyroid and hyperthyroid multinodular goiters. *Endocr. Rev.*, 3: 40-61.
- Studer, H., H. Gerber and H.J. Peter, 1989. Multinodular Goiter. In: *Endocrinology*, DeGroot, L.J. (Eds.). W.B. Saunders, Philadelphia, pp: 722-723.
- Summers, V.K. and S.J. Surtees, 1961. Thyrotoxicosis and heart disease. *Acta Med. Scand.*, 169: 661-671.
- Syriou, V., S.C. Plastiras, T. Paterakis, I. Moyssakis and P. Vlachoyiannopoulos, 2008. Severe reversible right heart failure in a patient with hyperthyroidism. *Int. J. Clin. Pract.*, 62: 334-336.
- Taillard, V., M Sardinoux, C. Oudot, P. Fesler and C. Rugale, 2011. Early detection of isolated left ventricular diastolic dysfunction m high-risk differentiated throid carcmoma patients on TSH-suppressive therapy. *Clin. Endocrinol.*, 75: 709-714.
- Tajik, J. and S. Nazifi, 2011. Serum concentrations of lipids and lipoproteins and their correlations together and with thyroid hormones in Iranian water buffalo (*Bulba/us bulbalis*). *Asian J. Anim. Sci.*, 5: 196-201.

- Tajiri, J., S. Hamasaki, T. Shimada, M. Morita, K. Higashi, S. Ohishi and T. Sato, 1986. Masked thyroid dysfunction among elderly patients with atrial fibrillation. *Jpn. Heart J.*, 27: 183-190.
- Tunbridge, W.M., D.C. Evered, R. Hall, D. Appleton and M. Brewis *et al.*, 1977. The spectrum of thyroid disease in a community: The Whicharn survey. *Clin. Endocrinol.*, 7: 481-493.
- Umana, E., C.A. Solares and M.A. Alpert, 2003. Tachycardia-induced cardiomyopathy. *Am. J. Med.*, 114: 51-55.
- Walker, J.D., F.A. Crawford, S. Kato and F.G. Spinale, 1994. The novel effects of 3,5,3'-triiodo-L-thyronine on myocyte contractile function and α -adrenergic responsiveness in dilated cardiomyopathy. *J. Thoracic Cardiovasc. Surg.*, 108: 672-679.
- Waring, A.C., S. Harrison, M.H. Samuels, K.E. Ensrud and E.S. Leblanc *et al.*, 2012. Thyroid function and mortality in older men: A prospective study. *J. Clin. Endocrinol. Metab.*, 97: 862-870.
- Weissel, M., 2001. Hyperthyroidism and heart. *Wien Klin Wochenschr*, 113: 157-161.
- Wong, S.M., H.F. Tse and C.W. Siu, 2011. Pulmonary hypertension and isolated right heart failure complicating amiodarone induced hyperthyroidism. *Heart Lung Circul.*, 21: 163-165.
- Yu, Y.H. and J.P. Bilezikian, 2000. Tachycardia-induced cardiomyopathy secondary to thyrotoxicosis: A young man with previously unrecognized Graves disease. *Thyroid*, 10: 923-927.
- Yue, W.S., B.H. Chong, X.H. Zhang, S.Y. Liao and M.H. Jim *et al.*, 2011. Hyperthyroidism-induced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure. *Clin. Toxicol.*, 74: 636-643.